scholarly journals An 89-Year-Old Man with COVID-19-Associated Coagulopathy Presenting with a Prolonged Partial Thromboplastin Time, Lupus Anticoagulant, and a High Titer of Factor VIII Inhibitor

2020 ◽  
Vol 21 ◽  
Author(s):  
Sanaz Ghafouri ◽  
Matthew Rettig ◽  
Kanwarpal S. Kahlon
Keyword(s):  
Factor Viii ◽  
Partial Thromboplastin Time ◽  
Lupus Anticoagulant ◽  
High Titer ◽  
Factor Viii Inhibitor ◽  
Viii Inhibitor

scholarly journals An Unusual Etiology for Elevation of Activated Partial Thromboplastin Time (aPTT) in SLE: Acquired Hemophilia and Lupus Anticoagulant

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Srikanth Seethala ◽  
Nathaniel P. Collins ◽  
George Comerci
Keyword(s):  
Factor Viii ◽  
Partial Thromboplastin Time ◽  
Lupus Anticoagulant ◽  
Activated Partial Thromboplastin Time ◽  
Factor Viii Inhibitor ◽  
Activity Levels ◽  
First Line ◽  
Acquired Hemophilia ◽  
Viii Inhibitor ◽  
Work Up

A 60-year-old female who has a history significant for diabetes, depression, and rheumatoid arthritis presented with a progressively enlarging hematoma of the left upper extremity. She was found to have an enlarging hematoma and an isolated elevation of activated partial thromboplastin time (aPTT). Lab work-up revealed low factor VIII activity levels and inhibitor titers at 13.38 Bethesda units (BU). Dilute Russell’s viper venom time (dRVVT) revealed a lupus anticoagulant. Hemostasis was achieved with factor VIII inhibitor bypassing activity (FEIBA) and inhibitor eradication with-rituxan after the failure of first-line treatment with cyclophosphamide and prednisone.

In Vitro Thrombogenicity Tests of Factor IX Concentrates

1979 ◽  
Vol 42 (05) ◽  
pp. 1355-1367 ◽  
Author(s):  
C V Prowse ◽  
A Chirnside ◽  
R A Elton
Keyword(s):  
Factor Viii ◽  
Partial Thromboplastin Time ◽  
Generation Time ◽  
Activated Partial Thromboplastin Time ◽  
Factor Ix ◽  
In Vitro Tests ◽  
Factor Viii Inhibitor ◽  
Factor Ixa ◽  
Viii Inhibitor

SummaryVarious factor IX concentrates have been examined in a number of in vitro tests of thrombogenicity. The results suggest that some tests are superfluous as in concentrates with activity in any of these tests activation is revealed by a combination of the non-activated partial thromboplastin time, the thrombin (or Xa) generation time and factor VIII inhibitor bypassing activity tests. Assay of individual coagulant enzymes revealed that most concentrates contained more factor IXa than Xa. However only a small number of concentrates, chiefly those that had been purposefully activated, contained appreciable amounts of either enzyme.

New Method for Quantifying Lupus Anticoagulant

1996 ◽  
Vol 2 (4) ◽  
pp. 237-240
Author(s):  
Roy Speck
Keyword(s):  
Factor Viii ◽  
Confidence Level ◽  
Lupus Anticoagulant ◽  
Heparin Therapy ◽  
Factor Ix ◽  
New Method ◽  
Factor Viii Inhibitor ◽  
Single Factor ◽  
Viii Inhibitor

A method is presented using a new reagent containing propylgallate for the quantitative determina tion of lupus anticoagulant. The amount of an optimized phospholipid standard required by the clotting reaction was found to be 32-50 μg/ml at a 95% confidence level, with a mean of 41 μg/ml. This method eliminates the ef fect of heparin therapy, coumadin therapy, factor-VIII inhibitor, factor-IX inhibitor, and single-factor deficien cies that afflict presently used lupus anticoagulant screen ing and confirmatory procedures. Using this method, it should be possible to detect lupus anticoagulant in pa tients at a much lower level and follow the effect of ther apy on lupus anticoagulant.

Acquired factor VIII inhibitor and positive lupus anticoagulant testing on silica clotting time

2014 ◽  
Vol 37 (1) ◽  
pp. 139-141
Author(s):  
H.-W. Ip ◽  
C.-C. So ◽  
Y.-Y. R. Leung ◽  
J.-Y. Chan ◽  
P. Sin ◽  
...  
Keyword(s):  
Factor Viii ◽  
Lupus Anticoagulant ◽  
Factor Viii Inhibitor ◽  
Clotting Time ◽  
Viii Inhibitor ◽  
Acquired Factor Viii Inhibitor

scholarly journals Successful management of life-threatening hemorrhage in a patient with synchronous lupus anticoagulant and factor VIII inhibitor

2002 ◽  
Vol 36 (4) ◽  
pp. 853-855 ◽  
Author(s):  
Hans A. Brings ◽  
John K. Waas ◽  
Keith R. McCrae ◽  
Henry R. Baele ◽  
Jerry Goldstone
Keyword(s):  
Factor Viii ◽  
Lupus Anticoagulant ◽  
Factor Viii Inhibitor ◽  
Successful Management ◽  
Life Threatening ◽  
Viii Inhibitor
Sign in / Sign up

Export Citation Format

Share Document